News | January 31, 2022
Cipla has strong traction in India and the US: ICICI Direct
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
The Thermo Scientific Orbitrap Exploris MX enables customer success by combining high-quality data with operational simplicity
Subscribe To Our Newsletter & Stay Updated
